TNFSF13
(Tumor Necrosis Factor (Ligand) Superfamily, Member 13 (TNFSF13))
Reaktivität
Maus
Wirt
Armenischer Hamster
Klonalität
Monoklonal
Konjugat
Dieser TNFSF13 Antikörper ist konjugiert mit PE
Applikation
Flow Cytometry (FACS)
Kreuzreaktivität
Human
Aufreinigung
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.
APRIL antikoerper, CD256 antikoerper, TALL-2 antikoerper, TALL2 antikoerper, TRDL-1 antikoerper, ZTNF2 antikoerper, 2310026N09Rik antikoerper, April antikoerper, Tall2 antikoerper, Trdl1 antikoerper, SLAN antikoerper, ANP32B antikoerper, april antikoerper, tnf13 antikoerper, TNLG7B antikoerper, TNF superfamily member 13 antikoerper, tumor necrosis factor (ligand) superfamily, member 13 antikoerper, acidic leucine-rich nuclear phosphoprotein 32 family member B antikoerper, TNFSF13 antikoerper, Tnfsf13 antikoerper, LOC494442 antikoerper, tnfsf13 antikoerper
Hintergrund
CD256 (APRIL, TNFSF13, TALL2, TRDL1) a transmembranal protein of 26 kD, forms a homotrimeric molecule that is cleaved from the cell surface resulting in the soluble form of APRIL, it also forms heterotrimers with BLyS. Its receptor are TNFRSF13b/TACI and TNFRSF17/BCMA. Expressed by T cells, B cells, dendritic cells, monocytes, and macrophages, APRIL induces proliferation of T and B cells, promotes IgA class switching, downregulates T-cell dependent antibody responses, and regulates the growth of a variety of tumor cells.